Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03564899 Active, not recruiting - Clinical trials for Breast Cancer Survivorship

The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study

Start date: February 13, 2017
Phase: N/A
Study type: Interventional

The Breast Cancer & Physical Activity Level (BC-PAL) pilot study is a randomized controlled pilot trial aimed at evaluating whether total physical activity levels, health-related fitness and patient reported outcomes are improved by promoting different intensities of physical activity participation within a home-based setting, and whether these improvements are maintained over the long-term, in inactive breast cancer survivors.

NCT ID: NCT03564782 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer

Start date: July 2018
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with triple negative breast cancer (TNBC).

NCT ID: NCT03564171 Not yet recruiting - Breast Cancer Clinical Trials

Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer

Start date: June 10, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for breast cancer.

NCT ID: NCT03563352 Not yet recruiting - Cholangiocarcinoma Clinical Trials

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Start date: July 30, 2018
Study type: Observational

This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer. Learning what participants like and dislike about their current or past used nutritional supplements may help doctor know how to improve them.

NCT ID: NCT03562832 Recruiting - Clinical trials for Metastatic Breast Cancer

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Start date: June 2018
Phase: Phase 2
Study type: Interventional

2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical activity in a prior Phase 1 study in a number of solid tumors. 2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome some of the PARP inhibitor resistance. The Phase 2 study is using 2x-121 DRP® biomarker in metastatic breast cancer patients to identify patients likely to respond to and benefit from treatment with 2X-121.

NCT ID: NCT03562637 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.

Start date: August 18, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, placebo controlled, study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 treatment, compared to placebo, in patients with early stage TNBC at high risk for recurrence.

NCT ID: NCT03562390 Active, not recruiting - Breast Cancer Clinical Trials

Irinotecan for Advanced and Metastatic Breast Cancer

Start date: April 1, 2017
Phase: Phase 2
Study type: Interventional

This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing anthracyclines and taxanes.

NCT ID: NCT03561740 Not yet recruiting - Breast Cancer Clinical Trials

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Start date: June 15, 2018
Phase: Phase 3
Study type: Interventional

Breast cancer is the most common malignant tumor in women. Recurrent or metastatic breast cancer is incurable. High risk patients usually have the following characteristics, such as, non-pCR after neoadjuvant therapy, lymph nodes positive, >2cm tumor size, HER2 overexpression, etc. Intensive targeted or chemo therapy could improve prognosis. Previous studies have shown the efficacy and feasibility of intensive treatment of capecitabine in non-pCR breast cancer patients. Given the metronomic capecitabine therapy is well tolerated, we designed this study to compare the efficacy and safety of adding metronomic capecitabine to standard adjuvant therapy for high risk HER2+ breast cancer patients.

NCT ID: NCT03560856 Not yet recruiting - Breast Cancer Clinical Trials

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

Start date: June 27, 2018
Phase: Phase 2
Study type: Interventional

The clinical efficacy of fulvestrant and/or palbociclib in the population of patients with metastatic lesions harboring ESR1 mutations was reported. In the PALOMA 3 study, the combination of Fulvestrant+ Palbociclib seems to be active in patients whose tumour harbours ESR1 mutations. This study will confirm these data on this population and will allow us to identify if other gene alterations or a genomic signature can correlate with fulvestrant +palbociclib resistance.

NCT ID: NCT03560531 Not yet recruiting - Breast Cancer Clinical Trials

A Study of ZN-c5 in Subjects With Breast Cancer

Start date: June 2018
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multicenter, sequential dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer who have progressed following endocrine therapy. ZN-c5 will be evaluated both as monotherapy and in combination with palbociclib (IBRANCE®).